Table 1.

An overview of cannabis based products and cannabinoids

	Medicinal products						Non-medicinal products
	Cannabis based products for medicinal use				Synthetic cannabinoids for medicinal use		Non-medicinal CBD products	Non-medicinal cannabis	Non-medicinal synthetic cannabinoids
Example	Bedrocan	Tilray	Sativex	Epidiolex	Dronabinol	Nabilone	CBD oil2	White Widow3	Spice4
Cannabinoid profile	THC +/−CBD	THC +/−CBD	THC:CBD ratio 1:1	CBD	THC	THC	High CBD, low THC	High THC, low CBD	Synthetic cannabinoid receptor agonists
Formulation	Herbal cannabis	Oil	Oromucosal spray	Oral solution	Capsule or liquid	Capsule	Varied; capsule and oil	Varied; herbal cannabis	Herbal, liquid, or powder
Licensed indications (UK)	None	None	Multiple sclerosis	None	None	Chemotherapy induced nausea and vomiting	Not medicinal products
Quality standards	Good manufacturing practice	Good manufacturing practice	Good manufacturing practice	Good manufacturing practice	Good manufacturing practice	Good manufacturing practice	No quality assurance
Affected by rescheduling (UK) on 1 November 2018?	Yes	Yes	No	No	No	No	No	No	No
Pre-amendment Schedule (UK)	1	1	4	Not scheduled	2	2	Not scheduled (if THC does not exceed 0.2%)	1	1
Post-amendment Schedule (UK)	2	2	4	Not scheduled	2	2	Not scheduled (if THC does not exceed 0.2%)	1	1
Can be prescribed in the UK?	Doctors on General Medical Council specialist register; named patient basis	Doctors on General Medical Council specialist register; named patient basis	Specialist doctors with expertise in treating multiple sclerosis	No restrictions on prescribing; named patient basis. Likely to be a specialist prescribing due to the proposed indications	No restrictions on prescribing; named patient basis	No restrictions on prescribing. Preferably administered in a hospital setting. GPs may prescribe once treatment initiated	No	No	No